Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1290 studies found for:    "Chronic myeloproliferative disorders"
Show Display Options
Rank Status Study
1 Completed Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
Conditions: Polycythemia Vera;   Essential Thrombocytosis;   Idiopathic Myelofibrosis;   Neutrophils;   Chronic Myeloproliferative Disorders
Intervention:
2 Active, not recruiting Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Conditions: Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: microarray analysis;   Genetic: polyacrylamide gel electrophoresis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Genetic: western blotting;   Other: chromatography;   Other: high performance liquid chromatography;   Other: immunoenzyme technique
3 Completed INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
4 Completed Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: decitabine;   Drug: romidepsin
5 Completed Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
Conditions: Chronic Myeloproliferative Disorders;   Leukemia
Intervention: Drug: PS-341
6 Completed Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: dexamethasone;   Drug: thalidomide
7 Terminated Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes
Interventions: Radiation: Total Body Irradiation;   Drug: Fludarabine;   Drug: Campath 1H
8 Completed Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
9 Completed Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
Conditions: Myelodysplastic Syndromes;   Myeloproliferative Disorders;   Blood and Marrow Transplant (BMT);   Myelodysplastic Syndromes (MDS);   Myeloproliferative Disorders (MPD)
Intervention: Procedure: nonmyeloablative allogeneic hematopoietic cell transplant
10 Active, not recruiting Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
Condition: Myeloproliferative Neoplasms
Intervention: Drug: Pomalidomide
11 Withdrawn Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
Conditions: Myeloproliferative Disorders;   Polycythemia Vera;   Essential Thrombocythemia;   Myelofibrosis;   Chronic Myeloid Leukemia
Intervention:
12 Completed Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases
Conditions: Myeloproliferative Disorders;   Pulmonary Hypertension
Intervention: Other: Echocardiography, spiroergometry, cardiac catheterization
13 Completed JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders
Condition: Myeloproliferative Disorders
Intervention: Biological: Blood samples and buccal swabs
14 Active, not recruiting Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
Conditions: Myeloproliferative Neoplasm;   Primary Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention: Drug: Mirabegron
15 Recruiting Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Condition: Chronic Myeloproliferative Neoplasms
Intervention: Drug: Givinostat
16 Unknown  Tipifarnib in Treating Patients With Myeloproliferative Disorders
Conditions: Leukemia;   Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Drug: tipifarnib
17 Completed Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: methotrexate;   Drug: therapeutic hydrocortisone;   Drug: thioguanine
18 Recruiting Registry of Older Patients With Cancer
Conditions: Chronic Myeloproliferative Disorders;   Cognitive/Functional Effects;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:
19 Recruiting Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm
Interventions: Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure
20 Terminated
Has Results
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: management of therapy complications;   Procedure: peripheral blood stem cell transplantation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years